Reduced Risk of Upper Gastrointestinal Ulcer Complications With Celecoxib, A Novel Cox-2 Inhibitor

Abstract

The incidence of UGI ulcer complications associated with celecoxib was 8-fold lower than with nonspecific NSAIDs. The incidence of ulcer complications observed in celecoxib-treated patients was similar to that in patients receiving placebo in the RCTs, and to that in non-NSAID users reported in the literature.